cemiplimab   Click here for help

GtoPdb Ligand ID: 10090

Synonyms: cemiplimab-rwlc | Libtayo® | REGN-2810 | REGN2810 | SAR-439684 | SAR439684
Approved drug Immunopharmacology Ligand
cemiplimab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Cemiplimab (REGN2810) is a fully human anti-PD-1 immuno-oncology biological therapeutic that was developed by Regeneron Pharmaceuticals [1-2]. This antibody was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies [4].
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.
Click here for help
1. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017)
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.
Mol Cancer Ther, 16 (5): 861-870. [PMID:28265006]
2. Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG. (2016)
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
J Immunother Cancer, 4: 70. [PMID:27879972]
3. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS et al.. (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med, 379 (4): 341-351. [PMID:29863979]
4. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M et al.. (2014)
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.
Proc Natl Acad Sci USA, 111 (14): 5153-8. [PMID:24706856]
5. Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O et al.. (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lancet, 397 (10274): 592-604. [PMID:33581821]